SecBot SecBot
PRESS-RELEASE ·Filed Mar 4, 2026

BWAY

BrainsWay
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor upcoming revenue guidance and clinic adoption metrics; the SWIFT protocol could accelerate commercial growth, especially if payer policies continue to ease. Watch for follow-on studies or additional insurance coverage changes.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.45
T+0 close · Mar 4, 2026 · via day close
Latest settled
+27.55%
T+60 · $15.88
Vs SPY
+17.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $12.45entry
  2. T+1 · 9mo ago +1.37%α +1.94% · $12.62
  3. T+5 · 8mo ago +10.60%α +11.94% · $13.77
  4. T+20 · 8mo ago +9.08%α +13.49% · $13.58
  5. T+60 · 6mo ago +27.55%α +17.46% · $15.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay released new clinical data demonstrating that its FDA-cleared SWIFT™ accelerated Deep TMS protocol for major depressive disorder achieves comparable remission and response rates to the standard protocol in significantly fewer treatment days, reducing the acute phase from 20 visits to just 6 half-days. The data show an 87.8% response rate and 78.0% remission rate, with median time to remission cut from 28 to 21 days, supporting improved patient access and retention.

Key Facts

  • SWIFT™ protocol reduces acute treatment phase from 20 visits over 4 weeks to 6 half-days, a ~70% reduction in clinic visits
  • 87.8% response rate and 78.0% remission rate achieved with SWIFT, comparable to standard protocol
  • Median time to remission decreased to 21 days vs. 28 days with standard treatment
  • 70% of patients no longer had severe quality-of-life impairment; ~60% returned to normal-range functioning
  • Evernorth Behavioral Health eliminated prior authorization for Deep TMS, improving payer access

Financial Impact

Potential for significantly increased treatment adoption due to reduced time burden and improved payer access, which could drive higher utilization and revenue over time

revenueutilizationmarket penetration

Risk Factors

  • Commercial adoption may lag despite clinical success due to provider inertia or reimbursement limitations
  • Forward-looking statements are subject to risks including regulatory delays, competition, and failure to scale

Market Snapshot

Exchange
OTC

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249244

US Market Status

Market Closed · Opens Wed (12h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026